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Abstract
Background: Models to predict disease course and long-term outcome based on clinical characteristics at disease
onset may guide early treatment strategies in juvenile idiopathic arthritis (JIA). Before a prediction model can be
recommended for use in clinical practice, it needs to be validated in a different cohort than the one used for
building the model. The aim of the current study was to validate the predictive performance of the Canadian
prediction model developed by Guzman et al. and the Nordic model derived from Rypdal et al. to predict severe
disease course and non-achievement of remission in Nordic patients with JIA.
Methods: The Canadian and Nordic multivariable logistic regression models were evaluated in the Nordic JIA
cohort for prediction of non-achievement of remission, and the data-driven outcome denoted severe disease
course. A total of 440 patients in the Nordic cohort with a baseline visit and an 8-year visit were included. The
Canadian prediction model was first externally validated exactly as published. Both the Nordic and Canadian
models were subsequently evaluated with repeated fine-tuning of model coefficients in training sets and testing in
disjoint validation sets. The predictive performances of the models were assessed with receiver operating
characteristic curves and C-indices. A model with a C-index above 0.7 was considered useful for clinical prediction.
Results: The Canadian prediction model had excellent predictive ability and was comparable in performance to the
Nordic model in predicting severe disease course in the Nordic JIA cohort. The Canadian model yielded a C-index
of 0.85 (IQR 0.83–0.87) for prediction of severe disease course and a C-index of 0.66 (0.63–0.68) for prediction of
non-achievement of remission when applied directly. The median C-indices after fine-tuning were 0.85 (0.80–0.89)
and 0.69 (0.65–0.73), respectively. Internal validation of the Nordic model for prediction of severe disease course
resulted in a median C-index of 0.90 (0.86–0.92).
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Conclusions: External validation of the Canadian model and internal validation of the Nordic model with severe
disease course as outcome confirm their predictive abilities. Our findings suggest that predicting long-term
remission is more challenging than predicting severe disease course.
Keywords: Juvenile idiopathic arthritis, Prediction, Validation, Outcome research, Remission
Background
Population-based studies show that juvenile idiopathic
arthritis (JIA) is a chronic childhood rheumatic disease
with diverse disease manifestations, courses, and progno-
ses [1–4]. Prognostic prediction models are increasingly
important tools for informed decision-making in medi-
cine [5, 6]. In a newly diagnosed patient with JIA, it can
be challenging to decide if a potent treatment with pos-
sible serious side effects should be started early in the
disease course. A well-performing prediction model can
help assess the risk of severe disease and hence guide de-
cisions on starting or stepping up disease-modifying an-
tirheumatic drugs, including biologic treatments. This
may facilitate individually tailored treatment strategies
within the so-called window of opportunity [7–10]. Be-
fore such prediction models can be recommended for
general use in clinical practice, we need to ensure they
have good predictive performance across different JIA
populations. Unfortunately, studies on development of
prediction models in pediatrics [11] and in JIA are
scarce [12–18]. As far as we know, no study has previ-
ously reported a quantitative external validation of pre-
diction models in JIA in a different population.
To address this knowledge gap, a collaboration has
been initiated between two prospective and well-defined
longitudinal cohort studies: the Research in Arthritis in
Canadian Children Emphasizing Outcomes (ReACCh-
Out) Cohort and the Nordic JIA cohort. The first results
of the collaboration are presented here and in the twin
study by Henrey et al. (part 2). These studies analyze
prediction models recently proposed by Guzman et al.
[17] and Rypdal et al. [19]. Guzman et al. constructed a
model for predicting severe disease course derived from
the ReACCh-Out study (the Canadian model). The
model had a C-index of 0.85 in internal validation in the
Canadian cohort. Rypdal et al. constructed a model for
prediction of non-achievement of remission (the Nordic
model), and this model had a C-index of 0.78 in internal
validation in the Nordic cohort.
In the present study, our aims were to validate the pre-
dictive ability of the Canadian model in the Nordic JIA
cohort and to internally validate the performance of the
Nordic model to predict severe disease course, an out-
come originally constructed from data in the Canadian
cohort [17, 20]. Conversely, the Nordic prediction model
was tested for these outcomes in the Canadian cohort,
with results presented in the twin paper by Henrey et al.
(part 2). The validated prediction models may in the fu-
ture be updated, harmonized, and eventually used as
clinical tools in decision-making regarding early individ-
ualized treatment in JIA.
Patients and methods
The Nordic JIA study is a prospective, longitudinal, mul-
ticenter cohort [2, 21]. Measures were taken to ensure a
population-based approach; all consecutive newly diag-
nosed JIA patients from 12 pediatric rheumatology cen-
ters in defined geographical areas of Denmark, Finland,
Norway, and Sweden were included if disease onset was
between January 1, 1997, and June 30, 2000, and the
International League of Associations for Rheumatology
criteria for JIA [2] were fulfilled. The aim was to have a
baseline visit 6 months after disease onset, and the pa-
tients were followed at regular visits with 1-to-3-year in-
tervals up to 8-years after disease onset.
The ReACCh-Out study is also a multicenter prospect-
ive study. A total of 16 pediatric rheumatology centers
across Canada participated, and consecutive patients with
newly diagnosed JIA were recruited between January 2005
and December 2010. The first visit occurred as soon as
possible after diagnosis, but the time from diagnosis to the
first visit could be up to 1 year. The inclusion criterion in
the Canadian prediction study was attendance in at least 6
of 8 study visits, which were scheduled every 6months for
2 years, and then yearly up to 5 years. It was also required
that information was available at least at one visit, for each
of the 5 clinical variables used to construct the severe dis-
ease course outcome [17].
Both studies collected extensive clinical and laboratory
data at the study visits as previously reported [17, 19].
Characteristics of the two study populations are pre-
sented in Table 1.
The current study is reported according to the TRIPOD
guideline (Transparent reporting of a multivariable predic-
tion model for individual prognosis or diagnosis) [4, 22].
Patients
The present study includes all patients from the Nordic
cohort with data available from at least a baseline and an
8-year visit. This includes 440 (88%) of the 500 patients
originally included at baseline. In contrast to the previ-
ous work on prediction models in the Nordic cohort
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[19], patients with systemic JIA are included in the
current study.
Outcomes
The main outcome predicted in the previous Nordic
study was non-achievement of remission at the 8-year
visit, which included patients with active disease, inactive
disease on medications, or inactive disease off medica-
tions for less than 12months. Inactive disease was de-
fined by the Wallace 2004 criteria, the current criteria at
the time the 8-year study was conducted [23, 24].
The main outcome in the Canadian study was severe
disease course. The method used to develop and define
this outcome was previously reported [17]. In summary,
the clinical JIA course was described according to five
variables: participant-defined quality of life and pain re-
ports, both assessed on 10-cm visual analogue scales
(VAS); active joint count; medication requirements; and
medication side effects. Based on this information, four
different clinical courses were identified by a clustering
algorithm. The main outcome, severe disease course, was
the union of the two worst groups, severe controlled
course and severe persistent course, as defined by
Guzman et al. [17].
In the present study, a version of the Canadian outcome
was constructed in the Nordic cohort using information
on four variables collected at the 8-year study visit. This
outcome is also denoted severe disease course, but the
construct variables in the Nordic cohort were the cumula-
tive active joint count, the remission status, the Childhood
Health Assessment Questionnaire disability index
(CHAQ), and the Physical Summary Score (PhS) derived
from the Child Health Questionnaire Parent form (CHQ-
PF50) [25]. The aim was to construct a severe disease
course group corresponding as closely as possible to the
outcome used in the ReACCh-Out prediction study. Ac-
cordingly, we used these four variables and a clustering al-
gorithm to divide the Nordic cohort in four disease course
groups. The two most severe courses were defined to have
a severe disease course. Characteristics of the four disease
course clusters in the Nordic JIA cohort are presented in
Additional file 1: Table S1.
We also constructed an alternative definition of the
outcome using five variables, the four described above in
addition to the pain-VAS report at the 8-year follow-up.
Both constructions corresponded reasonably well with
the construction in the ReACCh-Out study, and the re-
sults of the external validation of the Canadian model
were similar in the two cases. In both cases, we made a
series of choices and essentially tuned the construction
to obtain clusters that corresponded in relative size to
those found in the Canadian study. We used linear di-
mensionality reduction and then the K-means or the K-
medoids clustering algorithm [26] to construct clusters.
Predictors in the Nordic and the Canadian model
The baseline predictors that we considered as candidates for
the Nordic multivariable logistic regression model are previ-
ously published [19]. The following eight predictors consti-
tuted the final multivariable model: cumulative active joint
count; erythrocyte sedimentation rate (ESR) mm/hour, mea-
sured as a continuous variable; C-reactive protein (CRP) mg/
l, with values < 10mg/l considered to be normal; morning
stiffness > 15min; physician’s global assessment of disease
activity on a 10-cm VAS; presence of antinuclear antibodies
(ANA) analyzed by immunofluorescence on Hep-2cells and
tested at least twice with a minimum of 3months apart;
presence of human leucocyte antigen (HLA)-B27; and ankle
joint arthritis. The first five variables were included a priori
based on a clinical judgment and justified on the basis that
these variables are central in the American College of
Rheumatology (ACR) for clinical active disease [27].
The Canadian multivariable logistic regression model
used 16 variables: active joint count, psoriatic arthritis,
oligoarthritis, RF-negative polyarthritis, upper limb joint
involvement, symmetric joint involvement, RF positivity,
Table 1 JIA-study population in the Canadian ReACCh-Out and the Nordic JIA cohort
Characteristics Canadian development cohort Nordic validation cohort
Study design Prospective multicenter Prospective multicenter
Patient recruitment perioda January 2005–December 2010 January 1997–June 2000
Total participants, n 1497 500
Time from onset to baseline study visit, monthsb 5.8 (3.0–11.0) 7.0 (6.0–8.0)
Time from onset to outcome assessment, monthsb 49 (38–59)c 98 (95–102)
Participants in the current study, n 609 440
Inclusion criteria 6 of 8 study visitsd Baseline and 8-year study visit
Main outcome Severe disease course Non-achievement of remission
aNewly diagnosed JIA patients
bMedian interquartile range (IQR)
cSevere disease course outcome was assessed over time, not at a single point
dAdditionally, at least one value available for each of the five patient-relevant variables
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subtalar joint involvement, finger joint involvement, cer-
vical spine involvement, ankle joint involvement, pres-
ence of morning stiffness, hip joint involvement,
temporomandibular joint involvement, mid-foot involve-
ment, and the presence of enthesitis. Details regarding
measurement and assessment of these variables were
previously reported [17].
Model validation
This study presents external validation of the Canadian
model and internal validation of the Nordic model. The Can-
adian model was tested for its ability to predict severe disease
course and non-achievement of remission in a separate cohort
from the one used to build the model. The Canadian model
was first tested exactly as published by Guzman et al., and
also after fine-tuning, i.e., with re-estimated coefficients. The
Nordic model was tested for its ability to predict severe dis-
ease course by internal validation, involving repeated parti-
tioning of the cohort in multiple training sets for model
building and validation sets for model testing.
Statistical analyses
Rypdal et al. constructed multivariable logistic regression
models using a set of 5 pre-defined variables and a step-
wise forward selection method to obtain additional vari-
ables from a set of 29 candidate variables. Variables with
a P value > 0.05 were removed. Selections of variables
were performed in training sets, and no more than 10
predictor variables were allowed in each of the models.
The final model included 8 predictors, as previously de-
scribed [19].
Guzman et al. constructed their model through a ver-
sion of backwards elimination starting with a full model
of 52 predictors and retaining 16 predictor variables in
their multivariable logistic regression model. Both the
Nordic and the Canadian models underwent internal
validation with the repeated random split-sample tech-
nique and cross-validation in their respective cohorts.
External validation of the Canadian model
The model [17] is tested by computing the probability of
severe disease course and non-achievement of remission
according to the formula:
p ¼ 1
1þ e−A
where A = β0 + β1x1 +… + β16x16 is a linear combin-
ation of predictors. Apart from the active joint count, all
variables are dichotomous. In external validation, we
used the coefficients βi from the ReACCh-Out cohort
exactly as published [17]. A probability of severe disease
course and non-achievement of remission was computed for
each patient in the Nordic cohort, and these probabilities
were compared to the outcomes described above. By varying
the probability threshold, pairs of corresponding sensitivity
and specificity values were obtained, and consequently a re-
ceiver operating characteristic (ROC) curve. The area under
the curve (AUC), or C-statistic, was computed from the
ROC curve for each outcome. This is reported as the C-
index. For each outcome, the uncertainty in the C-statistic
was quantified by a standard bootstrapping (resampling)
method and reported as interquartile range (IQR).
Testing of the Canadian model after fine-tuning
This involved re-estimating the coefficients βi in subsets (train-
ing sets) of the Nordic cohort and evaluating the correspond-
ing models (using the same method) as described above on
disjoint validation sets. We used 500 repeated random splits
into training and validation sets, and the median C-statistics
with IQRs were computed. For each random split, we used
75% of available patients for training, and 25% for testing.
Internal validation of the Nordic model
The Nordic model was validated by constructing and
training models on training sets and tested on disjoint val-
idation sets as described above. For the Nordic model, the
training involved not only the estimation of coefficients βi,
but also the variable selection as reported [19]. The results
for prediction of non-achievement of remission have been
previously reported, but in the present study, we extended
this analysis to prediction of severe disease course. For
comparison, we also carried out this analysis for a univari-
ate logistic regression model with cumulative active joint
count at baseline as the only predictor. The sample size
was determined by the number of patients with available
data for analyses in the Nordic JIA cohort.
For the construction of the severe disease course outcome,
there were 1 or more missing values for 248 of the 440 pa-
tients. Since severe disease course is a data-driven outcome, it
was necessary to impute these missing values. For this pur-
pose, we used the linear dimension-reduction algorithm in
the Wolfram Mathematica software. The results presented
in this study are without imputation of missing data for the
predictor variables; thus, patients with 1 or more missing
predictor variables were omitted from the testing of that par-
ticular model. For the external validation of the Canadian
model, we lost 222 of 440 patients due to missing data in 1
or more of the 16 predictors. Most of these were missing
tests of RF positivity (repeated twice at least 3 months apart).
To test the effect of the missing predictor data on the main
result, we performed a sensitivity analysis where we imputed
missing data in predictor variables and re-tested the
Canadian model. Results did not change significantly.
The statistical analyses in the current study were per-
formed using Stata/MP version 15 and Wolfram Mathe-
matica version 11.3.0.0.
Rypdal et al. Arthritis Research & Therapy          (2019) 21:270 Page 4 of 10
Results
Among the 440 patients in the Nordic cohort, 98/440
(22%) were identified with a severe disease course. This
ratio is similar to the 125 (21%) of 609 patients identified
with a severe disease course in the ReACCh-Out study.
Altogether, 246/427 (58%) were not in remission off
medication at the 8-year visit. The general characteristics
of the 2 study populations are presented in Table 1, and
Table 2 Baseline clinical characteristics for patients in the ReACCh-Out and the Nordic JIA cohort according to severe disease course
or non-severe disease course
Characteristics ReACCh-Out development cohort Nordic validation cohort
Severe disease (n = 125) Non-severe (n = 484) Severe disease (n = 98) Non-severe (n = 342)
Age at onset, years 9.9 (5.4–12.0), n = 123 6.9 (2.5–10.7), n = 474 8.1 (2.9–11.0) 5.2 (2.3–9.0)
Female, n (%) 88 (70.4) 325 (67.1) 78 (79.6) 213 (62.3)
Disease onset to diagnosis, months 5.6 (2.4–13.9) 3.3 (1.6–6.4) 2.4 (1.4–5.1), n = 94 1.4 (1.4–2.8), n = 321
Disease onset to enrollment, months 8.8 (4.9–17.0) 5.5 (2.8–9.9) 6.0 (6.0–9.0) 7.0 (6.0–8.0)
JIA category, n (%)
Oligoarthritis 9 (7.2) 214 (44.2) 27 (27.6) 200 (58.5)
RF-neg. polyarthritis 44 (35.2) 85 (17.6) 37 (37.8) 57 (16.7)
RF-pos. polyarthritis 20 (16.0) 6 (1.2) 3 (3.1) 1 (0.3)
Systemic 10 (8.0) 37 (7.6) 2 (2.0) 15 (4.4)
Enthesitis-related 24 (19.2) 57 (11.8) 9 (9.2) 25 (7.3)
Psoriatic 4 (3.2) 32 (6.6) 1 (1.0) 5 (1.5)
Undifferentiated 14 (11.2) 53 (11.0) 19 (19.4) 39 (11.4)
Active joints, n (%)
Cervical arthritis 21 (16.8) 8 (1.7) 22 (22.7) 16 (4.7)
Finger arthritis 86 (68.8) 122 (25.2) 63 (65.0) 72 (21.1)
Ankle arthritis 78 (62.4) 140 (28.9) 61 (62.9) 137 (40.1)
Hip arthritis 35 (28.0) 34 (7.0) 19 (19.6) 45 (13.2)
Cumulative active joint counta 13 (4–26) 2 (1–4) 9 (5–14) 2 (1–5)
Physician global assessment VAS 5.3 (3.2–7.2) 2.3 (1.0–4.6) 2.4 (1.0–4.7), n = 75 1.0 (0.3–2.1), n = 173
Parents’ global assessment VAS 3.6 (1.8–5.7), n = 114 1.3 (0.3–3.5), n = 440 2.3 (1.0–5.0), n = 76 0.9 (0.0–2.5), n = 195
Pain VAS 5.0 (2.7–6.8), n = 114 2.0 (0.5–5.0), n = 440 3.4 (1.1–5.0), n = 75 0.8 (0.0–2.8), n = 192
CHAQ 0.9 (0.3–1.4), n = 109 0.3 (0.0–0.8), n = 408 0.9 (0.3–1.4), n = 78 0.1 (0.0–0.7), n = 200
Morning stiffness, n (%) 102/124 (82.3)b 334/447 (74.7)b 60/86 (69.8)c 60/254 (23.6)c
ESR mm/hour 20 (9–45), n = 119 20 (9–36), n = 433 16 (8–39), n = 77 14 (8–25), n = 281
CRP mg/l 5.8 (0.4–34.0), n = 98 2.0 (0.1–10.0), n = 371 0.0 (0.0–22.5), n = 80 0.0 (0.0–10.0), n = 274
ANA positive, n (%) 54 (43.0)d 233 (48.0)d 22/95 (23.2) 93/332 (28.3)
RF positive, n (%) 24 (19.2)d 21 (4.3)d 4/70 (5.7) 6/171 (3.5)
HLA B27 positive, n (%) 18 (14.4)d 46 (9.5)d 23/96 (24.0) 63/314 (20.1)
Treatment by first study visit, n (%)
NSAIDs 115/125 (92.0) 451/484 (93.2) 83/97 (85.6) 290/337 (86.1)
Joint injections 9/125 (7.2) 92/484 (19.0) 46/95 (48.4) 195/334 (58.4)
DMARDs 89/125 (71.2) 114/484 (23.6) 39/94 (41.5) 53/320 (16.6)
Biologics 2/125 (1.6) 0 0 0
Numbers are median interquartile range (IQR) unless otherwise specified
VAS visual analogue scale, CHAQ Childhood Health Assessment Questionnaire, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ANA antinuclear
antibodies, RF rheumatoid factor, HLA B27 Human Leucocyte Antigen B27, NSAID non-steroidal anti-inflammatory drug, DMARD disease modifying
antirheumatic drug
aThe Nordic cohort used the cumulative joint count within 6 months of disease onset, and the ReACCh-Out cohort used the active joint count at baseline
bMorning stiffness > 30min
cMorning stiffness > 15 min
dValues on ANA, RF, and HLA B7 for the Canadian cohort are after imputation
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detailed clinical characteristics of the groups of patients
with severe disease course in the two cohorts are pre-
sented in Table 2.
In the Nordic validation cohort, 66.2% were female.
The baseline visit took place at a median of 7 (IQR 6–8)
months after the first symptom of JIA, and the median
time for assessment of the outcome was 98 (IQR 95–
102) months after disease onset. Time from disease on-
set to JIA diagnosis was 1.6 (IQR 1.4–3.3) months. The
median age at disease onset was 5.5 (IQR 2.5–9.7) years.
In the Canadian development cohort, 67.9% were fe-
male. The median time from disease onset to the base-
line visit was 5.8 (IQR 3–11) months. The outcome was
assessed on patients that attended at least six of eight
planned visits, which correspond to a follow-up of 3 to
5 years. Time from first symptom to diagnosis was 3.7
(IQR 1.8–7.3) months, and the median age at disease on-
set was 8.4 (IQR 3.4–11.9) years.
Model validation
The external validation with severe disease course as out-
come resulted in a C-index of 0.85, and bootstrapping
gave an estimated IQR of 0.83–0.87. For non-achieve-
ment of remission, the C-index was 0.66 (IQR 0.63–0.68)
(Table 3). The corresponding ROC curves for the exter-
nal validation are shown in Fig. 1, and the calibration
plots are shown in the Additional file 2: Figure S1. The
alternative construction of severe disease course, based
on five rather than four variables at the 8-year follow-up,
gave a C-index of 0.84 with an IQR of 0.82–0.87. After
imputation of missing data in predictor variables the C-
index was 0.83.
After fine-tuning in training sets, the Canadian model
had a median C-index of 0.85 (IQR 0.80–0.89) with se-
vere disease course as outcome (Table 3 and Fig. 2a).
The same analysis with non-achievement of remission as
outcome gave a C-index of 0.69 (IQR 0.65–0.73)
(Table 3, Fig. 2b). The model variables and their corre-
sponding βi-coefficients for the original ReACCh-Out
model and the model fine-tuned to the Nordic popula-
tion are presented in Table 4.
We also performed internal validation of our Nordic
model using severe disease course as outcome. This gave a
median C-index of 0.90 (IQR 0.86–0.92) (Table 3, Fig. 2c).
Ultimately, we tested a very simple prediction model with
cumulative active joint count at baseline as the only pre-
dictor. For this model, a C-index of 0.85 (IQR 0.82–0.88)
was estimated. The corresponding ROC curve is presented
in Additional file 3: Figure S2.
Discussion
A clinically useful prediction model for long-term out-
come in JIA should be tested for reliability and accuracy
across cohorts, countries, and ethnicities to avoid over-
estimating the predictive performance of the model. To
our knowledge, the two studies presented in this issue
are the first where prediction models for unfavorable
outcomes in JIA are tested on cohorts completely differ-
ent to those used to construct the models.
The main result of this study is that the external valid-
ation of the Canadian prediction model yielded excellent
predictive performance with a C-index of 0.85 (IQR
Table 3 C-indices for testing of Canadian and Nordic prediction models





Original Canadian model 0.85 (0.83–0.87) 0.66 (0.63–0.68) External validation (bootstrapping)
Canadian model fine-tuned for Nordic
population
0.85 (0.81–0.89) 0.69 (0.65–0.73) Fine-tuning (repeated random splits)
Nordic model 0.90 (0.86–0.92) 0.78 (0.72–0.82)a Internal validation (repeated random
splits)
C-indices with median interquartile range (IQR)
C-index presented includes patients with systemic JIA, except for athe C-index for the Nordic model and the outcome non-achievement of remission previously
published by Rypdal et al. [19]
Fig. 1 Receiver operating characteristic (ROC) curves showing
external validation of the Canadian prediction model in the Nordic
JIA cohort. Blue curve: using severe disease course as outcome. C-
index with IQR = 0.85 (0.83–0.87). Red curve: using non-achievement
of remission as outcome. C-index with IQR = 0.66 (0.63–0.68)
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0.83–0.87) for severe disease course in the Nordic cohort.
The result is consistent with the internal validation in
the Canadian cohort, where a C-index of 0.85 was ob-
tained [17]. The Canadian model was also tested after
fine-tuning on repeated random splits, giving a similar
result to the ones in external validation. Internal valid-
ation of the Nordic model also indicated excellent per-
formance (C-index of 0.90) for predicting a severe
disease course.
In all comparisons, C-indices for prediction of severe
disease course were higher than for prediction of non-
achievement of remission.
Recently, several prediction models in JIA have been
published, but predictive abilities are suboptimal, and
none of them have been externally validated in an en-
tirely different population [14–16, 18, 19]. The current
study highlights two key points: (1) The choice of out-
come to be predicted is essential for predictive perform-
ance and perhaps more important than model design.
(2) Prediction models based on a few key variables may
have similar predictive ability to more complex models,
at least for the outcomes examined in this study.
The first point is supported by the comparison of non-
achievement of remission and severe disease course. It seems
the latter defines a narrower and more homogeneous group
of patients that is easier to identify and predict. In our opin-
ion, severe disease course is clinically relevant because it
captures a group of JIA patients most severely affected by
the disease. This adverse outcome may correspond better
with the threshold in many countries for initiating biologic
treatment and therefore be a better prediction target to
guide early aggressive treatment [8–10, 28].
The second point is supported by observing that in
this study, the predictive abilities of the most complex
models are not much better than those of simpler
models. The Nordic model for prediction of non-
achievement of remission was designed with specific
conditions in place to ensure model simplicity. It is com-
parable to the Canadian model in performance. How-
ever, the Canadian model is based on 16 variables and
may be more difficult to use in clinical practice, even
though an available online calculator is easy to use. Be-
sides its predictive performance, one of the key features
of a good clinical prediction rule is simplicity [29].
To further investigate the potential of very simple pre-
diction models, we also assessed a univariate logistic
Fig. 2 Receiver operating characteristic (ROC) curves showing results
of fine-tuned models in the Nordic JIA cohort for different
outcomes. a Fine-tuned Canadian prediction model using severe
disease course as outcome. b Fine-tuned Canadian prediction model
using non-achievement of remission as outcome. c Internal
validation of Nordic prediction model using severe disease course
as outcome
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regression model using cumulative active joint count
during the first 6 months after disease onset as the only
predictor. The model achieved high predictive perform-
ance for severe disease course, and we take this as an in-
dication that model simplification is feasible. However,
the high predictive ability of this very simple model may
be explained by the dependence between cumulative ac-
tive joint count at baseline and the cumulative active
joint count later in the disease.
Simple prediction models may perform well for a large
group of JIA patients, where the total number of joints
affected explains much of the disease burden, but they
may be of little use for patients with, for example, sys-
temic JIA or enthesitis-related arthritis, where the sever-
ity of the disease may be strongly associated with other
clinical features [30]. The heterogeneity of JIA is there-
fore an argument against oversimplified prediction
models, and multivariable models may have greater ap-
plicability across the whole spectrum of JIA. While sep-
arate models for different JIA categories may be more
accurate [15], they may add complexity to prediction.
Study strengths and limitations
The main strength of this work is that we validate a model
constructed in the Canadian cohort in the completely sep-
arate Nordic cohort. Both studies were multicenter, pro-
spective, longitudinal studies and collected extensive
clinical information. However, both the Canadian and
Nordic models were constructed starting from a large
number of clinical variables, which may have increased
the risk of retaining uninformative predictors in the
models and overfitting. A weakness of our study is missing
data in predictor and outcome variables, which is a com-
mon problem in prediction studies [31]. We have tried to
address this issue by imputing the values for the variables
used in the data-driven outcome and by not omitting
patients who lack information on predictor variables.
Selecting only patients with complete data may lead to
biased results.
In conclusion, we found excellent predictive perform-
ance of both the Canadian and Nordic prediction models
for predicting a severe disease course in children with
JIA. Severe disease course was identified using an impli-
cit, data-driven clustering method. Identifying an object-
ive definition of a severe disease course was beyond the
scope of this paper, but a clinical definition of severe dis-
ease course in JIA is clearly needed. Future studies on
prediction models in JIA are necessary, focusing not only
on constructing simplified prediction models, but also
on determining improved disease-outcome definitions in
JIA. Once objective outcome definitions are in place, we
can use the knowledge gained from the Nordic-
Canadian collaboration to develop new models that can
be tested in a third and independent cohort. The ultim-
ate step will be testing the model in a randomized con-
trolled trial to verify if it can significantly improve
patient outcomes. The aim is to develop models that can
be used in every day clinical practice. We have
Table 4 Canadian prediction model with respective βi coefficients before and after fine-tuning in the Nordic JIA cohort
Predictor variables in the Canadian model Original ReACCh-Out cohorta Fine-tuned in the Nordic cohortb
Constant Intercept = − 2.92 Intercept = 2.76
Active joint count, n = 440 0.18 0.21
Psoriatic arthritis, n = 440 − 1.23 − 1.40
Oligoarthritis, n = 440 − 1.14 − 0.72
RF-negative polyarthritis, n = 440 − 0.49 − 0.68
Upper limb joint involvement, n = 440 0.75 − 1.11
Symmetric joint involvement, n = 439 − 0.88 0.68
RF positivity, n = 241 1.31 − 1.06
Subtalar joint involvement, n = 439 − 1.42 − 2.81
Finger joint involvement, n = 439 − 0.31 1.31
Cervical spine involvement, n = 439 0.84 0.38
Ankle joint involvement, n = 439 0.48 − 0.25
Presence of morning stiffness, n = 340 0.56 1.64
Hip involvement, n = 439 0.06 − 0.50
TMJ-involvement, n = 439 1.50 0.09
Mid foot involvement, n = 439 0.54 0.39
Presence of enthesitis, n = 437 0.86 1.26
aCoefficients found by logistic regression in the Canadian cohort, previously reported [17]
bThe changes in coefficients after fine-tuning in the Nordic JIA cohort
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developed a smartphone application for the Nordic
model, and online web-based calculators exist for both
the Nordic (http://predictions.no) and the Canadian
(https://shiny.rcg.sfu.ca/jia-sdcc/) models [17, 19]. These
tools can easily be extended to new models. As we better
understand the accuracies and limitations of the models,
physicians may incorporate them in their overall assess-
ments to improve outcome in JIA.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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